Anurag Das, MD
Urology · Staten Island, NYNPI 1891733101
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Procept Biorobotics Corporation accounts for 62.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,421 and has fallen 98.4% since, to $23 in 2025. That places this record below the midpoint for urology clinicians in NY, where the typical reported total is $2,467.
Across 14 payments — averaging $156.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- Boston Scientific$541
- Richard Wolf Medical Instruments Corp.$146
- AbbVie$97
- Calyxo, Inc.$23
- Axonics, Inc.$19
What the payments were for
- Consulting fees$1,27558%
- Travel & lodging$45021%
- Food & beverage$46421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 4 | $1,362 |
| Boston Scientific | 6 | $541 |
| Richard Wolf Medical Instruments Corp. | 1 | $146 |
| AbbVie | 1 | $97 |
| Calyxo, Inc. | 1 | $23 |
| Axonics, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,275
How this compares
$2,188 in reported general payments places this provider in the 45th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 14 | $8,994 |
| Dutasteride | 34 | $1,698 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 65 | $1,302 |
| Tamsulosin Hcl | 101 | $1,257 |
| Finasteride | 17 | $229 |
Paid to pharmacies, not to this prescriber.
Other urology in Staten Island
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.